Anti-Fibrinolytic Drugs - Southeast Asia

In Southeast Asia, the Anti-Fibrinolytic Drugs market is projected to see a significant increase in revenue, with an estimated value of US$197.10m in 2024.
It is expected that this market will continue to grow steadily, with an annual growth rate (CAGR 2024-2029) of 5.44%.
By 2029, the market volume is projected to reach US$256.80m.
When compared globally, United States is expected to generate the highest revenue in this market, with an estimated value of US$9.86bn in 2024.
In Southeast Asia, the demand for anti-fibrinolytic drugs has seen a significant increase due to the rising prevalence of cardiovascular diseases in the region.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Southeast Asia is a growing market with increasing demand for these drugs due to various factors.

Customer preferences: Customers in Southeast Asia have shown a growing preference for Anti-Fibrinolytic Drugs due to the increasing prevalence of bleeding disorders and surgeries. These drugs are also preferred due to their effectiveness in reducing blood loss during surgeries and minimizing the need for blood transfusions.

Trends in the market: The market for Anti-Fibrinolytic Drugs in Southeast Asia is witnessing a significant growth due to the increasing number of surgeries being performed in the region. The rise in medical tourism in countries such as Thailand, Singapore, and Malaysia has also contributed to the growth of the market. The demand for these drugs is expected to increase further due to the aging population in the region, which is more prone to bleeding disorders and requires surgeries.

Local special circumstances: In Southeast Asia, there are certain local circumstances that are affecting the growth of the Anti-Fibrinolytic Drugs market. For instance, in Indonesia, the government has implemented a universal healthcare system, which has increased the demand for these drugs. In the Philippines, the market for Anti-Fibrinolytic Drugs is growing due to the increasing number of private hospitals and clinics.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Southeast Asia is also influenced by underlying macroeconomic factors. The increasing GDP of countries in the region has led to an increase in healthcare spending, which has contributed to the growth of the market. The rise in disposable income and the growing middle class in the region has also led to an increase in demand for better healthcare facilities, which has further boosted the market for Anti-Fibrinolytic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.